Moderna's Intismeran Hits Phase 3 Milestone in Melanoma, Eyes 2027 FDA Filing and Broader Cancer Trials
Moderna's intismeran achieved its Phase 3 endpoint in melanoma, triggering planned 2027 FDA submission and multi-cancer expansion. Supporting Phase 2b data showed meaningful recurrence reduction, yet full Phase 3 results are still pending. Regulatory and manufacturing hurdles will determine whether individualized mRNA vaccines reach broader oncology practice.
Evidence quality remains preliminary. The current report rests on an executive interview without peer-reviewed primary endpoint publication or independent data monitoring committee disclosure. An adequately powered Phase 3 manuscript with prespecified subgroup analyses and manufacturing consistency data is required before clinical adoption can be confidently projected.
Moderna: Intismeran receives FDA approval by September 2027 contingent on Phase 3 recurrence-free survival hazard ratio below 0.70 in the final analysis.
Sources (3)
- [1]STAT News(https://www.statnews.com/2026/10/26/biotech-news-moderna-ceo-on-whats-next-after-intismeran-success/)
- [2]NEJM Phase 2b mRNA-4157 Study(https://www.nejm.org/doi/full/10.1056/NEJMoa2303387)
- [3]FDA Draft Guidance on Personalized Cancer Vaccines(https://www.fda.gov/media/177000/download)